

Poster	Rapid Fire	Poster	Торіс	Title	Presenter	Country
Number	Session	Group				
PP-001		Group A	Basic Science – Developmental biology	Mapping the transcriptional landscape of neuroblastoma across animal models and humans	Aliki Grammatikaki	Germany
PP-002		Group A	Basic Science – Developmental biology	Evaluating Combinatorial Effects of 13-cis-RA and DFMO on Neuroblastoma Differentiation Outcomes	Annie Wan Ting Xia	US
PP-003		Group A	Basic Science – Developmental biology	Single-cell multiomic characterization of the TH-MYCN 9464D mouse model of neuroblastoma	Cedar Schloo	Germany
PP-004		Group A	Basic Science – Developmental biology	Decoding Post-Chemotherapy Neuroblastoma Maturation using Chromium Single Cell Gene Expression Flex and Nanopore Sequencing	Eun Seop Seo	South Korea
PP-005		Group A	Basic Science – Developmental biology	Assembly factor for spindle microtubules (ASPM) is a regulator of neuroblastoma cell proliferation and differentiation	Hedwig Elisabeth Deubzer	Germany
PP-006	Rapid Fire Session 1	Group A	Basic Science – Immunology & Tumor Microenvironment	Imaging mass cytometry reveals the spatial network of immune cells in neuroblastoma	Francisca Bergsma	Netherlands
PP-007		Group A	Basic Science – Immunology & Tumor Microenvironment	Circulating extracellular vesicles released by neuroblastoma cells carry the disialoganglioside GD2	Martin Auber	Germany
PP-008		Group A	Basic Science – Immunology & Tumor Microenvironment	Induction chemotherapy leads to increased tumour inflammation in high-risk neuroblastoma patients	Neha Jain	Australia
PP-009		Group A	Basic Science – Immunology & Tumor Microenvironment	YAP1 activation impacts neuroblastoma cell interaction and growth	Peris Ruka	Germany
PP-010		Group A	Basic Science – Immunology & Tumor Microenvironment	Unraveling Tumor Heterogeneity in Neuroblastoma Through Single-Cell-Resolved Clonal Analysis	Roshni Biswas	Germany
PP-011		Group A	Basic Science – Immunology & Tumor Microenvironment	Neuroblastoma phenotype shift and immunosuppressive microenvironment after chemotherapy in single-cell perspective	Rui Dong	China
PP-012		Group A	Basic Science – Immunology & Tumor Microenvironment	VCAN+ macrophages promote neuroblastoma migration and adrenergic to mesenchymal transition via the HB-EGF/ERBB signaling axis	Rumeysa Biyik Sit	US
PP-013		Group A	Basic Science – Immunology & Tumor Microenvironment	Interaction between gangliosides and the tumor environment in neuroblastoma	Saskia Wagner	Germany
PP-014		Group A	Basic Science – Immunology & Tumor Microenvironment	Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic signature	Shenglin Mei	US
PP-015		Group A	Basic Science – Immunology & Tumor Microenvironment	Losartan induces apoptosis, decouples hypoxia from VEGF expression, and disrupts extracellular matrix deposition in neuroblastoma xenografts	Sonia Lorena Hernandez	US
PP-016		Group A	Basic Science – Immunology & Tumor Microenvironment	Mapping the tumor microenvironment of neuroblastoma with single-cell resolved spatial transcriptomics	Svea Beier	Germany
PP-017		Group A	Basic Science – Immunology & Tumor Microenvironment	High expression of BCL11A may lead to a decrease of T cells with CD8+ perforin+ in neuroblastoma	Xiaojun Yuan	China
PP-018		Group A	Basic Science – Immunology & Tumor Microenvironment	Gut microbiota signatures are associated with the toxicity of anti-GD2 immunotherapy in neuroblastoma	Yi Que	China
PP-019		Group A	Basic Science – Immunology & Tumor Microenvironment	T-Cell Receptor Diversity and Specificity in High-Risk Neuroblastoma: A Report from the Children's Oncology Group	Yiyue Jiang	Canada
PP-020		Group A	Basic Science – Immunology & Tumor Microenvironment	The surgery-related proinflammatory tumor microenvironment impacts on tumoral growth. Protumoral molecular effects in a mouse model of neuroblastoma	Ana Lourdes Luis Huertas	Spain
PP-021		Group A	Basic Science – Molecular analyses (proteo epigenomics)	Improved data set integration for cancer scRNA-seq data with anglemania	Aaron Kollotzek	Germany
PP-022		Group A	Basic Science – Molecular analyses (proteo epigenomics)	Association of RNA expression for GD2-synthetic enzymes GD3 and GD2 synthase with GD2 expression in neuroblastoma cell lines	Caezaan Keshvani	US
PP-023		Group A	Basic Science – Molecular analyses (proteo epigenomics)	Chemotherapy-induced transcriptional states change in MYCN-amplified neuroblastoma	Carla Hamilcaro	Germany
PP-024		Group A	Basic Science – Molecular analyses (proteo epigenomics)	FHD-286, a small molecule inhibitor of the SWI/SNF ATPases SMARCA2/4 blocks neuroblastoma phenotypic switching	Carly M. Sayers	US
PP-025		Group A	Basic Science – Molecular analyses (proteo epigenomics)	Scrutizing GJC1 Moonlighting Functions as Novel Dependency Factor in Neuroblastoma	Carolien Van Damme	Belgium
PP-026		Group A	Basic Science – Molecular analyses (proteo epigenomics)	Deciphering the RNA-Binding Dynamics of MYC Family Proteins through Integrative Bioinformatic and Experimental Approaches	Francisco Montesinos Expósito	Germany
PP-027		Group A	Basic Science – Molecular analyses (proteo epigenomics)	Upfront Comprehensive Genomic Profiling in High-Risk Neuroblastoma Patients in Russia	Garik Barisovich Sagoyan	Russia
PP-028		Group A	Basic Science – Molecular analyses (proteo epigenomics)	Non-canonical roles of RCoR2 in MYCN-driven neuroblastoma as a partner of the adrenergic core regulatory circuitry	Giorgio Milazzo	Italy
PP-029		Group A	Basic Science – Molecular analyses (proteo epigenomics)	The role of METTL1 in cell proliferation via m7G methylation in neuroblastoma	Harry May	US
PP-030		Group A	Basic Science – Molecular analyses (proteo epigenomics)	Epigenetic and in-vivo modifiers of GD2 expression in mouse models for neuroblastoma	Hiroyuki Yoda	US
PP-031		Group A	Basic Science – Molecular analyses (proteo epigenomics)	Research status and development trends of omics in neuroblastoma a bibliometric and visualization analysis	Huizhong Niu	China
PP-032		Group A	Basic Science – Molecular analyses (proteo epigenomics)	The R2 Platform: a Public Resource for Neuroblastoma Data Analysis and Visualization intended for Biomedical Researchers	Jan Koster	Netherlands
PP-033		Group A	Basic Science – Molecular analyses (proteo epigenomics)	Cohesin-mediated 3D genome structure defines Neuroblastoma oncogenic transcriptome	Jeeyoun Kang	US
PP-034		Group A	Basic Science – Molecular analyses (proteo epigenomics)	YAP suppresses downstream target genes through the recruitment of the PRC2 complex to promote therapy resistance in neuroblastoma	Jenny Shim	US



Poster	Rapid Fire	Poster	Торіс	Title	Presenter	Country
Number	Session	Group				
PP-035		Group A	Basic Science – Molecular analyses (proteo epigenomics)	Copper chelation modulates YTHDF2 RNA-binding protein localization, global translation, and RNA methylation (m6A) in neuronal cancers	Jessica L Bell	Australia
PP-036		Group A	Basic Science – Molecular analyses (proteo epigenomics)	Embryonic cell state transitions define tumor heterogeneity in paraganglioma and neuroblastoma	Jiacheng Zhu	Sweden
PP-037		Group A	Basic Science – Molecular analyses (proteo epigenomics)	Mendelian Randomization Analysis Based on Single-Cell Transcriptomes Identifies Key Genes in Neuroblastoma with Bone Marrow Metastasis	Aiguo Liu	China
PP-038		Group A	Basic Science – Molecular	Potential Roles of CDGSH Iron-Sulfur Domain 1 (CISD1) Proteins in the Pathogenesis and	Jyun Hong Jiang	Taiwan
PP-039		Group A	Basic Science – Molecular	Transcriptional regulation of Neuroblastoma cellular beterogeneity by STAG1- and STAG2-	Kaitlyn A Tremble	LIS
11 000		oloupin	analyses (proteo epigenomics)	cohesin	Rangin A. Hemble	00
PP-040		Group A	Basic Science – Molecular analyses (proteo epigenomics)	Gangliosides based stratification may identify ultra-high risk Neuroblastoma patients	Khalifa El Malki	Germany
PP-041	Rapid Fire Session 1	Group A	Basic Science – Molecular analyses (proteo epigenomics)	Reconstructing evolution of high-risk neuroblastoma from single-nuclei DNA sequencing data	Magdalena Seiffert	Germany
PP-042		Group A	Basic Science – Molecular analyses (proteo epigenomics)	Amplified {MYCN} Alters Neuroblastoma's Persulfidation Status	Michael Müller	Germany
PP-043	Rapid Fire Session 1	Group A	Basic Science – Molecular analyses (proteo epigenomics)	Charting Adrenergic and Mesenchymal Interconversion Through {In Vivo} Single-Cell Barcoding RNA Sequencing in Neuroblastoma	Stefano Di Giulio	US
PP-044		Group A	Clinical – Biomarkers & Imaging	Extracellular vesicles-derived nucleolin as a novel biomarker in neuroblastoma patients	Martina Morini	Italy
PP-045		Group A	Clinical – Biomarkers & Imaging	Validating Tumor Evolution Timing as a Prognostic Biomarker for Neuroblastoma: Implications for Risk Classification	Maximilia Eggle	Germany
PP-046		Group A	Clinical – Biomarkers & Imaging	cfDNA 5-hydroxymethylcytosine profiles identify immune landscape alterations in high-risk	Yuqing Xue	US
PP-047		Group A	Clinical – Biomarkers & Imaging	Association of Beta3-adrenoreceptor expression with staging and prognosis in patients affected by neuroblastoma	Stefania Crucitta	Italy
PP-048		Group A	Clinical – Biomarkers & Imaging	Improved Evaluation of Minimal Residual Disease in Bone Marrow of High-Risk Neuroblastoma: A Retrospective Observational Study	Noriyuki Nishimura	Japan
PP-049		Group A	Clinical – Biomarkers & Imaging	MONALISA – A SIOPEN pragmatic clinical trial to monitor neuroblastoma relapse with liquid biopsy sensitive analysis	Sabine Taschner Mandl	Austria
PP-050		Group A	Clinical – Biomarkers & Imaging	LIBERTY: LIquid Biopsy for rElapsed/RefracTorY neuroblastoma - a pan-Canadian pilot study using a clinically validated liquid biopsy platform	Sarah Cohen Gogo	Canada
PP-051		Group A	Clinical – Biomarkers & Imaging	Circulating Tumor Cell Clusters as Liquid Biomarkers for the Diagnosis and Prognosis of Neuroblastoma	Xiuli Yuan	China
PP-052		Group A	Clinical – Clinical research	Individualized tumor-informed circulating tumor DNA analysis for therapeutic response and recurrence monitoring of neuroblastoma	Suying Lu	China
PP-053		Group A	Clinical – Biomarkers & Imaging	Functional imaging with MIBG and FDG PET in high-risk neuroblastoma patients who require Extended Induction therapy for poor end of Induction response	Megan M Lilley	US
PP-054		Group A	Clinical – Clinical research	18F-Meta Fluorobenzyl Guanidine (MFBG) PET imaging of Neuroblastoma: Lesional analysis comparing MFBG with MIBG scans	Shakeel Modak	US
PP-055		Group A	Clinical – Clinical research	A Clinical Observational Study of Dinutuximab Beta as First-Line Maintenance Treatment for Patients with High-Risk Neuroblastoma in China	Xuedi Yu	China
PP-056	Rapid Fire Session 1	Group A	Clinical – Clinical research	Survival of relapsed/refractory neuroblastoma patients treated with dinutuximab beta long term infusion depends on FC gamma receptor and NK cells	Holger N Lode	Germany
PP-057		Group A	Clinical – Clinical research	RAPID: A Pilot Study of the Rapid Infusion of Dinutuximab	Sara Jane Onyeama	US
PP-058		Group A	Clinical – Clinical research	Improved Pain Throughout Chemoimmunotherapy Cycles in Patients with Relapsed & Refractory Neuroblastoma	Sara Jane Onyeama	US
PP-059		Group A	Clinical – Clinical research	Repeated Chemoimmunotherapy Series Results in Response and Survival in Patients with Relapsed and Refractory Neuroblastoma	Sara Jane Onyeama	US
PP-060		Group A	Clinical – Clinical research	Intensification of treatment with immunochemotherapy in metastatic high-risk neuroblastoma patients after inadequate response to induction therapy	Sophia Gunzer	Germany
PP-061	Rapid Fire Session 1	Group A	Clinical – Clinical research	Phase 1 Trial of universal donor NK cell infusions with temozolomide, irinotecan, and dinutuximab in patients with relapsed/refractory neuroblastoma	Keri A Streby	US
PP-062		Group A	Clinical – Clinical research	Real-World Data of Dinutuximab beta for relapsed/refractory neuroblastoma: A single-center experience	Suyi Kang	China
PP-063		Group A	Clinical – Clinical research	Response and outcome of high-risk neuroblastoma patients treated with infusion of anti-GD2 antibody ch14.18/CHO: A single -center study	Tingting Liu	China
PP-064		Group A	Clinical – Survivorship	Real-World Use of Dinutuximab Beta for High-Risk Neuroblastoma in Clinical Settings in France: The QUATUOR Study	Gudrun Schleiermacher	France
PP-065		Group A	Clinical – Clinical research	Pulmonary Toxicity Associated with Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients with Neuroblastoma	Wei Wei	US
PP-066		Group A	Clinical – Clinical research	Naxitamab-based treatment for patients with high-risk, refractory, or progressive neuroblastoma: a prospective, multicenter trial	Yizhuo Zhang	China
PP-067		Group A	Clinical – Clinical research	Lorlatinib Monotherapy or Combination Therapy in ALK-driven High-risk/Refractory/Relapsed Neuroblastoma: A Prospective Clinical Study	Yizhuo Zhang	China
PP-068		Group A	Clinical – Clinical research	Toxicity profile in patients with neuroblastoma: a comparison of chemoimmunotherapy versus chemotherapy and immunotherapy used separately	Urszula Zebrowska	Poland



Poster	Rapid Fire	Poster	Торіс	Title	Presenter	Country
Number	Session	Group				
PP-069		Group A	Clinical – Clinical research	Survival of patients with neuroblastoma (NB) between 1979 and 2018: report from the Italian Neuroblastoma Registry (RINB)	Stefania Sorrentino	Italy
PP-070		Group A	Clinical – Clinical research	Survival and treatment outcomes within the Canadian Relapse/Refractory High-Risk Neuroblastoma (CANOE) Registry	Shampavi Sri Haran	Australia
PP-071		Group A	Clinical – Clinical research	Concordance of NANT Response Criteria v2.0 (NANTRCv2.0) with International Neuroblastoma Response Criteria-2017 (INRC-2017)	Michael Migotsky	US
PP-072	Rapid Fire Session 1	Group A	Clinical – Clinical research	Neuroblastoma in older children, adolescents and young adults: An updated report from the International Neuroblastoma Risk Group (INRG)	Rebecca J. Deyell	Canada
PP-073	Rapid Fire Session 1	Group A	Clinical – Clinical research	KIR ligand mismatched allogeneic cord blood transplantation reduces bone marrow relapse in high-risk neuroblastoma stage M	Shinsuke Kataoka	Japan
PP-074		Group A	Clinical – Clinical research	Patterns of pulmonary toxicity following busulfan administration in high risk neuroblastoma	Vickyanne Carruthers	Australia
PP-075		Group A	Clinical – Clinical research	Results of a phase 2 study of IDRF-based surgical decisions and stepwise treatment intensification for patients with intermediate-risk neuroblastoma	Tomoko lehara	Japan
PP-076		Group A	Clinical – Clinical research	The clinical characteristics and prognosis of children with neuroblastoma carrying ARID1A/B gene	Yi Zhang	China
PP-077		Group A	Clinical – Clinical research	Nutritional status of children at diagnosis of high-risk neuroblastoma in Brazil: a multicentric pilot study	Vicente Odone Filho	Brazil
PP-078		Group A	Clinical – Clinical research	Using Ketamine Boluses in a United States Outpatient Clinic Setting for Naxitamab infusion in Relapsed/Refractory Neuroblastoma	Teresa Herriage	US
PP-079		Group A	Clinical – Survivorship	International Benchmarking of Childhood Cancer Survival by Tumour Stage – The BENCHISTA Project: Results for Neuroblastoma	Adela Cañete Nieto	Spain
PP-080		Group A	Clinical – Clinical research	Long-term complications in survivors of neuroblastoma of the intermediate/high risk group	Tatyana Shamanskaya	Russia
PP-081		Group A	Clinical – Survivorship	Late Effects following high risk neuroblastoma treatment	Fiona Herd	UK
PP-082		Group A	Clinical – Survivorship	Spectrum of Late Effects in Cohort of High-Risk Neuroblastoma Survivors in Singapore	Shui Yen Soh	Singapore
PP-083		Group A	Clinical – Survivorship	UK wide retrospective analysis of spinal cord compression in peripheral neuroblastic tumours in childhood	Juliet C Gray	US
PP-084		Group A	Clinical – Survivorship	Should cervical neuroblastomas be managed differently from other anatomical sites? Evidence-based rationale from a new retrospective multicenter study	Patrick Barakat	France
PP-085		Group A	Clinical – Biomarkers & Imaging	Case Report: Germline SMARCA4 Variant in a Child with Bilateral Neuroblastoma	Shifra Ash	Israel
PP-086		Group A	Clinical – Clinical research	Serial busulfan drug monitoring in patients with high-risk neuroblastoma shows high intra- and interpatient variance	Sveva Alice Castelli	Germany
PP-087		Group A	Clinical – Clinical research	Clinical characteristics and therapeutic outcomes of infants and young neuroblastoma children with spinal cord compression	FuLi	China
PP-088		Group A	Developmental Therapeutics – Immunology	Pre-treatment with ferroptosis-inducers enhances NK cell immunotherapy infiltration in high- risk neuroblastoma	Adriana Mañas	Spain
PP-089		Group A	Developmental Therapeutics – Immunology	Amplifying T Cell Power: A Dual-Target Approach for Neuroblastoma	Alice Vitali	Germany
PP-090		Group A	Developmental Therapeutics – Immunology	Developing next-generation CAR T cells with improved homing and elimination of both tumor and immunosuppressive cells of the microenvironment	Anna Lena Spierling	Germany
PP-091		Group A	Developmental Therapeutics – Immunology	Anti-CD40 and Epigenetic Modifier Inhibitors to Augment Treatment of High-Risk Neuroblastoma	Anqi Gao	US
PP-092		Group A	Developmental Therapeutics – Immunology	A game of hide and seek: targeting neuroblastoma's escape from immunotherapy	Beatrice Piotto	Netherlands
PP-093		Group A	Developmental Therapeutics – Immunology	Armoring CAR T cells with IL12 to improve efficacy and persistence in the neuroblastoma tumor microenvironment	Carlotta Caramel	Germany
PP-094		Group A	Developmental Therapeutics – Immunology	Stimulating natural killer cell cytotoxicity with inhibition of polyamine synthesis and TGFb signaling	Christina Sophia Turn	US
PP-095		Group A	Developmental Therapeutics – Immunology	Anti-N-glycolyl GM3 vaccine Racotumomab in patients with High-Risk Neuroblastoma. An open-label, single-arm, multicenter phase 2 study in Argentina	Guido Andres Felizzia	Argentina
PP-096		Group A	Developmental Therapeutics – Molecular Targeting	Therapy pressure driven metabolic reprogramming in high-risk neuroblastoma patients	Natarajan Aravindan	US
PP-097		Group A	Developmental Therapeutics – Molecular Targeting	Tumorspheres: A new 3D model to study GD2 therapy, lineage heterogeneity, and motility in neuroblastoma	Piotr Jung Sillah	US
PP-098		Group A	Developmental Therapeutics – Molecular Targeting	Regulation Of Crosstalk and Signaling Switches Between RAF1 And MST2 Pathways in Neuroblastoma	Rashmi Sharma	Ireland
PP-099		Group A	Developmental Therapeutics – Molecular Targeting	Targeted Radiosensitization in High-Risk Neuroblastoma: A High-Throughput Drug Screening Discovery	Sammy Se Whee Park	Sweden
PP-100		Group A	Developmental Therapeutics – Molecular Targeting	Targeting Teneurin 4 suppresses tumor growth and induces differentiation in neuroblastoma	Sara Abu Ajamieh	Sweden
PP-101		Group A	Developmental Therapeutics – Molecular Targeting	A backwards approach to GD2 immunofluorescence in human neuroblastoma tissue samples: from staining to slicing	Sara Peggion	Germany
PP-102		Group A	Developmental Therapeutics – Molecular Targeting	Development of a Novel Abemaciclib-based CDK4/6/9 PROTAC Degrader with Potent Anti- Proliferative Effect in Neuroblastoma	Stijn Couwenbergh	Netherlands



Poster Number	Rapid Fire Session	Poster Group	Торіс	Title	Presenter	Country
PP-103		Group A	Developmental Therapeutics – Molecular Targeting	A novel Trametinib combination therapy for high-risk neuroblastoma targeting the MAPK signalling pathway	Sukriti Krishan	Australia
PP-104		Group A	Developmental Therapeutics – Molecular Targeting	Reprogramming the immunosuppressive tumor microenvironment by armoring murine GPC2 CAR T cells with CXCR2	Sydney L. Roth	US
PP-105		Group A	Developmental Therapeutics – Molecular Targeting	Identification of NCYM inhibitor that induces mitotic cell death in {MYCN}-amplified neuroblastoma cells	Ummi Maryam Zulfin	Japan
PP-106		Group A	Developmental Therapeutics –	APR-246 (Eprenetapopt) induces ferroptosis and synergizes with sulfasalazine and RAS-	Vid Mlakar	Switzerland
PP-107		Group A	Developmental Therapeutics – Molecular Targeting	Evaluating RAS inhibition in neuroblastoma as a therapeutic approach	Vinuri Dileshi Bulathsinhala	Germany
PP-108		Group A	Developmental Therapeutics – Molecular Targeting	Utilization of Antibody Drug Conjugates for Targeted Ferroptosis Induction in Neuroblastoma	Yeo Eun Yi	Germany
PP-109		Group A	Developmental Therapeutics – Molecular Targeting	Deciphering adrenergic to mesenchymal transition in neuroblastoma through identity- specific gene regulatory networks	Zengyan Yang	Germany
PP-110		Group A	Developmental Therapeutics – Preclinical models of disease	Unveiling the epigenetic drivers of metastatic neuroblastoma using mouse models	Adrià Molero Valenzuela	Spain
PP-111		Group A	Developmental Therapeutics – Preclinical models of disease	Neuroblastoma matrix-free patient-derived organoids recapitulate individual tumor histological, transcriptomic and functional characteristics	Amos Loh	Singapore
PP-112		Group A	Developmental Therapeutics – Preclinical models of disease	The potential of BCL-xL degradation as a strategy to eliminate chemotherapy-resistant neuroblastoma persister cells	Matteo Calafatti	US
PP-113		Group A	Developmental Therapeutics – Preclinical models of disease	Neuroblastoma Patient-Derived Xenografts and Cell Lines from Postmortem Blood as Models to Understand and Reverse Therapy Resistance	Balakrishna Koneru	US
PP-114	Rapid Fire Session 1	Group A	Developmental Therapeutics – Preclinical models of disease	A syngeneic MYCN-driven murine neuroblastoma allograft model for TCR mimetic CAR T cell preclinical therapeutics	Elisabeth Posthill	US
PP-115		Group A	Developmental Therapeutics – Preclinical models of disease	Transcriptomic profiling of in vitro and in vivo neuroblastoma models predicts response to targeted treatments	Ellora Hui Zhen Chua	France
PP-116		Group A	Developmental Therapeutics – Preclinical models of disease	MicroRNA Therapy Enhances Chemotherapeutic Effects for High-Risk Neuroblastoma	Erin G Brown	US
PP-117		Group A	Developmental Therapeutics – Preclinical models of disease	Preclinical models for functional oncology and investigation of TWIST1 implication in neuroblastoma: set up of 3D spheroids and in ovo xenografts	Estelle Guillot	Switzerland
PP-118		Group A	Developmental Therapeutics – Preclinical models of disease	Acquired resistance to temozolomide in the Th-MYCN mouse as a clinically-relevant platform to evaluate therapeutic against high-risk neuroblastoma	Evon Poon	UK
PP-119		Group A	Developmental Therapeutics – Preclinical models of disease	Immunocompetent Mouse Model of Primary, Recurrent, and Metastatic Neuroblastoma (NB)	Ferro Nguyen	US
PP-120		Group A	Developmental Therapeutics – Preclinical models of disease	Multi-omics Integration of Transcriptomics and Metabolomics Reveals Novel Predictive Biomarkers for Survival in Neuroblastoma Patients	He Sijia	China
PP-121	Rapid Fire Session 1	Group A	Developmental Therapeutics – Preclinical models of disease	A novel {MYCN}-driven mouse model to allow lineage tracing of neuroblastoma cells	Lisa Werr	Germany
PP-122	Rapid Fire Session 1	Group A	Developmental Therapeutics – Preclinical models of disease	An immunocompetent human B7H3 neuroblastoma mouse model for preclinical development of immunotherapies	Thomas J Jackson	UK
PP-123		Group B	Basic Science – Developmental biology	A CRISPR-Cas9 screen uncovers lineage state-specific regulation of inflammatory signaling	Matthew Shapiro	US
PP-124	Rapid Fire Session 2	Group B	Basic Science – Developmental biology	Inferring the evolution of structural genomic alterations in neuroblastoma by linked-read whole-genome sequencing	Christoph Bartenhagen	Germany
PP-125		Group B	Basic Science – Developmental biology	Modeling embryonal neuroblastoma tumorigenesis using human pluripotent stem cells	Ilayda Özel	Germany
PP-126		Group B	Basic Science – Developmental biology	The Neural Crest Origins of Neuroblastoma: Investigating Initiation Mechanisms via Transcriptional Profiling and 3D Organoid Modeling	Jenny Hsin	UK
PP-127		Group B	Basic Science – Developmental biology	Transcription factor 4 promotes CRC target gene transcription	Kevin W Freeman	US
PP-128		Group B	Basic Science – Developmental biology	Neuroblastoma graft in the avian embryo reveals initial seeding of extra-sympathico-adrenal tissues, opening new aetiological hypotheses of tumor foci	Luce Roseiro	France
PP-129		Group B	Basic Science – Developmental biology	Enhanced expression of ribosomal assembly and rRNA-modifying proteins associates with aggressive neuroblastoma cell phenotypes	Lukas Sourada	Czech Republic
PP-130		Group B	Basic Science – Developmental biology	ALK-activating mutations mediate the expansion of precancerous intra-adrenal sympathoblasts during embryonic development	Maya El Natour	Switzerland
PP-131		Group B	Basic Science – Developmental biology	Neuroendocrine Inactivity Defines a {MYCN}-Amplified, Ferroptosis-Sensitive Neuroblastoma Subgroup	Michael Müller	Germany
PP-132		Group B	Basic Science – Developmental biology	A Novel Zebrafish Model of Multifocal Disease and Spontaneous Tumor Regression	Nicole Anderson	US
PP-133	Rapid Fire Session 2	Group B	Basic Science – Developmental biology	MYCN overexpression biases human sympatho-adrenergic development towards progenitor cells causing neuroblastoma-like tumor xenografts	Stéphane Van Haver	US
PP-134		Group B	Basic Science – Immunology & Tumor Microenvironment	The development of a custom spatial transcriptomics platform to study cellular heterogeneity induced by targeted therapies in neuroblastoma	Hanne Van Droogenbroeck	Belgium
PP-135		Group B	Basic Science – Immunology & Tumor Microenvironment	Hijacking of the bone marrow niche by metastatic neuroblastoma cells	Ilse Timmerman	Netherlands
PP-136		Group B	Basic Science – Immunology & Tumor Microenvironment	Increased pre-clinical anti-tumor efficacy of B7H3 CAR-T cells against localized and disseminated neuroblastoma when combined with low-dose radiation	Israrul H. Ansari	US



Poster	Rapid Fire	Poster Crown	Торіс	Title	Presenter	Country
DD 127	36221011	Group B	Basic Science - Immunology &	Tarreting autophagy in neuroblastoma: Inhibiting VDS24 to enhance anti-GD2 immunotherany	liawen Zhang	211
FF-137		Gloup B	Tumor Microenvironment		Jawen Zhang	03
PP-138		Group B	Basic Science – Immunology &	Spatial transcriptomics exploration of the primary neuroblastoma microenvironment unveils	Joachim Tetteh Siaw	Sweden
			Tumor Microenvironment	novel paracrine interactions		
PP-139		Group B	Basic Science – Immunology &	LMO1 Overexpression Promotes Neuroblastoma Metastasis by Reprograming Tumor-	Ke En Tan	Malaysia
DD 140		Croup P		Associated Macrophages	Marta Emparador	Cormony
PP-140		Group B	Tumor Microenvironment	modeling and targeting the tumor microenvironment in therapy resistant neuroblastoma	Marta Emperador	Germany
PP-141		Group B	Basic Science – Immunology &	Bone marrow-derived extracellular vesicles of high-risk neuroblastoma patients carry RNAs	Martina Morini	Italy
			Tumor Microenvironment	shaping the tumor microenvironment		-
PP-142		Group B	Basic Science – Immunology &	Novel Cellular Immunotherapy for High-risk Neuroblastoma Using Anti-GD2 Antibody-	Masafumi Iguchi	Japan
			Tumor Microenvironment	Producing Mesenchymal Stem Cells		
PP-143		Group B	Basic Science – Immunology &	TAMs and CAFs Drive AMT in Neuroblastoma via TGF β and JAK/STAT3 Pathways	Meng Hua Lee	US
DD 144		Group B	Basic Science - Immunology &	Pro Angiogenic Potential of Cancer Educated Rone Marrow Mesenchymal Stem Colls is	Nansan Sau Vin Lam	Hong Kong
FF-144		Group B	Tumor Microenvironment	Suppressed by miR-15a with Anti-Neuroblastoma properties		Tiong Kong
PP-145		Group B	Basic Science – Immunology &	Histotripsy has an abscopal effect and induces an adaptive immune response in a	Natalia Antonides Jensen	US
			Tumor Microenvironment	neuroblastoma syngeneic model		
PP-146		Group B	Basic Science – Immunology &	RD3: A facet of tumor cellular plasticity and neuroblastoma immune evasion synergy	Natarajan Aravindan	US
			Tumor Microenvironment			
PP-147		Group B	Basic Science – Immunology &	Circulating cell-in-cell tumor cells with neutrophil signature are hematogenous metastasis-	Xiuli Yuan	China
PP-148	-	Group B	Basic Science – Molecular	Development of a digital PCR TERT/TERRA quantification assay in neuroblastoma	Bram De Wilde	Belgium
11-140		oroup b	analyses (proteo epigenomics)		biam be wilde	Detgium
PP-149		Group B	Basic Science – Molecular	Targeting Casein Kinase 2 For Undruggable LMO1-Dependent Neuroblastoma	Kok Siong Yeo	US
			analyses (proteo epigenomics)			
PP-150		Group B	Basic Science – Molecular	β -hydroxybutyrate ameliorates neuroblastoma cachexia-induced fat loss via AGPAT2 β -	Ling Tao	China
			analyses (proteo epigenomics)	hydroxybutyrylation		
PP-151		Group B	Basic Science – Molecular	MYCN drives neuroblastoma oncogenesis via molecular clock and metabolic disruption	Lingzhi Li	US
PP-152		Group B	Basic Science – Molecular	Identification of tumor genetic variants in pediatric neuroblastoma patients from Southern	Luciane Regina Cavalli	Brazil
102		oroup D	analyses (proteo epigenomics)	Brazil	Luciano nogina caram	Diden
PP-153		Group B	Basic Science – Molecular	Deciphering neuroblastoma clonal evolution via single-cell mitochondrial genomics	Marie Cotta	Germany
			analyses (proteo epigenomics)			
PP-154		Group B	Basic Science – Molecular	Exploring the role of cancer predisposing variants in neuroblastoma through whole exome	Mario Capasso	Italy
DD 155		Group B	analyses (proteo epigenomics)	sequencing of a large italian conort	Marius Ludwig	Cormany
FF-100		Group B	analyses (proteo epigenomics)	TAPI emances mesenchymal-type gene expression in neuroblastoma ceus	Marius Luuwig	Germany
PP-156	Rapid Fire	Group B	Basic Science – Molecular	Proteomic insights into extracellular vesicles in neuroblastoma biology	Martin Auber	Germany
	Session 2		analyses (proteo epigenomics)			
PP-157		Group B	Basic Science – Molecular	Single-cell RNA sequencing of circulating tumor cells of neuroblastomas	Masato Kojima	Japan
			analyses (proteo epigenomics)			
PP-158		Group B	Basic Science – Molecular	Prognostic impact of genomic alterations and clinical markers in Japanese high-risk	Miki Ohira	Japan
PP-159		Group B	Basic Science – Molecular	Internetastatic spread is a recurrent phenomenon in pediatric malignancies	Natalie Andersson	Sweden
1. 100		oroup D	analyses (proteo epigenomics)			01100011
PP-160		Group B	Basic Science – Molecular	Gene signature of high-risk neuroblastoma patient-derived xenografts associated with drug	Nighat Noureen	US
			analyses (proteo epigenomics)	resistance to cyclophosphamide + topotecan		
PP-161		Group B	Basic Science – Molecular	ABLIM3 promotes Neuroblastoma Metastasis through Cell Adhesion Molecule Signaling	Qiang Zhao	China
DD 162		Croup P	analyses (proteo epigenomics)	Pathways: Insights from Integrate Machine Learning	Qiang Zhao	China
FF-102		Group B	analyses (proteo epigenomics)	NGAR O FTOILIOUS NEUroblastollia FTOgression via initibiting p55-Dependent Fathway	Qiang Zhao	China
PP-163		Group B	Basic Science – Molecular	Core Transcriptional Regulatory Circuit-Regulated IGF2BP3 Stabilizing E2F2 mRNA via m6A	Ran Zhuo	China
			analyses (proteo epigenomics)	modification in Neuroblastoma		
PP-164		Group B	Basic Science – Molecular	Decoding Neuroblastoma Evolution: Plasma Proteome Signatures for Prognostic Predictions	Roza Sürme Mizrak	Germany
			analyses (proteo epigenomics)			
PP-165		Group B	Basic Science – Molecular	Landscape of DNA repair deficiency in patients with neuroblastoma as assessed by a nediatric precision oncology program	Sarah Cohen Gogo	Canada
PP-166		Group B	Clinical – Biomarkers & Imaging	I iquid Bionsy approaches in the SIOPEN Network for Neuroblastoma Research	Godelieve Andrea Tytgat	Netherlands
		oroup D			o o do no ro r indrou r j (gat	
PP-167		Group B	Clinical – Biomarkers & Imaging	Diagnostic and prognostic potential of Catecholamines in neuroblastoma: a report of the	Godelieve Andrea Tytgat	Netherlands
				SIOPEN Catecholamine Committee		
PP-168		Group B	Clinical – Biomarkers & Imaging	Impact of MYCN amplification on response rate and survival in high-risk neuroblastoma: One	Godelieve Andrea Tytgat	Netherlands
DD 100		Org	Olinical Disconstant Oliveria	size does not fit all when assessing response evaluation	Lodwig Elissbert	Cormani
FF-109		отопр в	Gunical – Biomarkers & Imaging	freduced risk stratification of pediatric neuroplastorna based on MRI-derived radiomics features	Deubzer	Germany
PP-170		Group B	Clinical – Biomarkers & Imaging	Identifying miRNAs as predictive markers of good prognosis in neuroblastoma	Hiroaki Kondo	Japan



Poster	Rapid Fire	Poster	Торіс	Title	Presenter	Country
Number	Session	Group				
PP-171		Group B	Clinical – Biomarkers & Imaging	Sensitive detection of minimal residual disease and immunotherapy targets by bone marrow multi-modal liquid biopsy analysis in high-risk neuroblastoma	Marie Bernkopf	Austria
PP-172		Group B	Clinical – Biomarkers & Imaging	Novel spatial multi-omics for characterization of neuroblastoma	Ioanna Tsea	Sweden
PP-173		Group B	Clinical – Biomarkers & Imaging	Detection and analysis of ATRX aberrations in neuroblastoma	Denis Kachanov	Russia
PP-174		Group B	Clinical – Biomarkers & Imaging	Benzyl Guanidine and Norepinephrine Transporters: Closing the Data Gap	Jehron Pura Bryant	US
PP-175		Group B	Clinical – Biomarkers & Imaging	The prognostic impact of chromosome 11q loss in stage 4S/MS neuroblastoma	Jessica Theißen	Germany
PP-176		Group B	Clinical – Biomarkers & Imaging	Using machine learning to identify GD2 negative circulating tumour cells in neuroblastoma patients	Deborah A. Tweddle	UK
PP-177		Group B	Clinical – Biomarkers & Imaging	Systematic review of publisehd biomarkers during or after induction chemotherapy in patients with high-risk neuroblastoma: a BORNEO project	Lucas Moreno	Spain
PP-178		Group B	Clinical – Biomarkers & Imaging	Whole Genome Sequencing (WGS) analysis from neuroblastoma patients in the North East of England	Kyriaki Karapiperi	UK
PP-179		Group B	Clinical – Clinical research	Can elevated LDH levels be considered as a prognostic marker in children with neuroblastoma in resource-limited settings?	Roberta Gomes Ribeiro Gonçalves Pinto	Brazil
PP-180		Group B	Clinical – Clinical research	Safety of ALK Inhibitors in Combination with Eflornithine (DFMO) in High-Risk Neuroblastoma (HRNB)	Giselle Saulnier Sholler	US
PP-181	Rapid Fire Session 2	Group B	Clinical – Clinical research	Survival Outcomes in Patients with High-Risk Neuroblastoma on Eflornithine (DFMO) Maintenance: Matched External Control Analysis at 7-Year Follow-Up	Giselle Saulnier Sholler	US
PP-182	Rapid Fire Session 2	Group B	Clinical – Clinical research	Dinutuximab administration during Induction does not increase the development of HACA during Post-Consolidation, a report from COG ANBL17P1	Ankita Shahi	US
PP-183		Group B	Clinical – Clinical research	Safety of Naxitamab + Granulocyte Macrophage Colony Stimulating (GM -CSF) in Combination with Induction Chemotherapy in High-Risk Neuroblastoma (HRNB)	Jacqueline Kraveka	US
PP-184		Group B	Clinical – Clinical research	Unexpected negative association of anti-GD2 IgA antibody response with survival after GD2/GD3 ganglioside vaccine treatment of high-risk neuroblastoma	Irene Y Cheung	US
PP-185		Group B	Clinical – Clinical research	A phase 1 trial of pretargeted radioimmunotherapy with GD2-SADA: ¹⁷⁷ Lu-DOTA in patients with high-risk neuroblastoma and other GD2+ solid tumors	Janet M. Yoon	US
PP-186		Group B	Clinical – Clinical research	Administration of Chemotherapy via Peripheral IVs for Patients with Stage MS Neuroblastoma	Kevin Campbell	US
PP-187		Group B	Clinical – Clinical research	Intraventricular Chemotherapy Options for Patients with CNS Neuroblastoma (NB)	Shakeel Modak	US
PP-188	Rapid Fire Session 2	Group B	Clinical – Clinical research	Administration of Intracerebroventricular Dinutuximab in the Treatment of CNS Neuroblastoma and Determination of CSF Pharmacokinetics	Michael Migotsky	US
PP-189		Group B	Clinical – Clinical research	Exploring process mining to understand and improve operational processes and protocol adherence in neuroblastoma treatment	Lieve Tytgat	Netherlands
PP-190		Group B	Clinical – Clinical research	HRNB: results with myeloablation(ABMT), being autologous cells collected after exposure to MIBG-I131(MIBG), plus allogenic dendritic cell vaccines(DV)	Nathalia Halley	Brazil
PP-191		Group B	Clinical – Clinical research	A single cycle of anti-GD2 before peripheral blood stem cell collection (PBSCC) for the treatment of high-risk neuroblastomas (HRNB)	Nathalia Halley	Brazil
PP-192		Group B	Clinical – Clinical research	METRO-NB 2012: A phase II multicenter trial of metronomic treatment in children and adolescents with recurrent or progressive neuroblastoma	Marc Hoemberg	Germany
PP-193		Group B	Clinical – Clinical research	Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The Children's Cancer and Leukaemia Group (CCLG) UK Experience	Menna Shamma	UK
PP-194		Group B	Clinical – Clinical research	Neuroblastoma in Older Age Group: What is Different and What is Not	Mohamed Fawzy Hassan	Egypt
PP-195		Group B	Clinical – Clinical research	Impact of early nutritional intervention on high risk neuroblastoma patients	Mohamed Fawzy Hassan	Egypt
PP-196		Group B	Clinical – Clinical research	Prognostic Factors Impacting Overall Survival Post-Relapse in High-Risk Neuroblastoma: Children's Oncology Group (COG) Results from 2000-2019	Monica Davini	US
PP-197		Group B	Clinical – Clinical research	Pseudoprogression and subsequent shrinkage of refractory/relapsed neuroblastoma induced by GAIA-102: an interim report of the single-agent cohort in	Naonori Kawakubo	Japan
PP-198		Group B	Clinical – Clinical research	Exploring compassionate/off-label therapies for relapsed/refractory neuroblastoma beyond chemo immunotherapy/ ALK inhibitors: the SACHA-France study	Pablo Berlanga	France
PP-199		Group B	Clinical – Clinical research	Bone marrow evaluation in neuroblastomas: bone marrow aspirates have little additional value over trephine biopsies	Rixt S. Bruinsma	Netherlands
PP-200		Group B	Clinical – Clinical research	Only mIBG positive post surgery residues impact on outcomes in patients with stage 4 neuroblastoma: results from the HR-NBL1/SIOPEN trial	Ruth Ladenstein	Austria
PP-201		Group B	Clinical – Clinical research	Pediatric Neuroblastoma: Clinical Feature Analysis, Treatment Dilemma Breakthrough and Optimization Strategy Exploration	Huizhong Niu	China
PP-202		Group B	Clinical – Clinical research	Enhanced Recovery After Neuroblastoma Surgery	Kara Kennedy	US
PP-203		Group B	Clinical – Clinical research	Analysis of Postoperative Complications in 205 Neuroblastoma Patients Based on the International Neuroblastoma Surgical Report Form (INSRF)	Huanmin Wang	China
PP-204		Group B	Clinical – Clinical research	Bridging the Gap in Surgical Oncology Training: A Patient-Specific Neuroblastoma Simulator	Lucas Krauel	Spain



Poster Number	Rapid Fire Session	Poster Group	Торіс	Title	Presenter	Country
PP-205		Group B	Clinical – Local and focal disease control	Surgeons' Experiences and Perspectives on Immersive Virtual Reality for Neuroblastoma Surgical Planning: Preliminary Insights	Lucas Krauel	Spain
PP-206		Group B	Clinical – Local and focal disease control	Acute Renal Failure and Continuous Renal Replacement Therapy in MS Neuroblastoma: A Case Series and Literature Review	Max Cohen	US
PP-207		Group B	Clinical – Local and focal disease control	Successful administration of 131I-MIBG therapy in a patient with bilateral nephrostomies: A case report	Cassandra Olsen	US
PP-208		Group B	Clinical – Local and focal disease control	Impact of residual primary tumor on the long-term quality of life in patients with non-high-risk neuroblastoma	Shigehisa Fumino	Japan
PP-209		Group B	Clinical – Local and focal disease control	Radiation therapy to metastatic sites among patients with high-risk neuroblastoma in first- line therapy	Tatyana Shamanskaya	Russia
PP-210		Group B	Clinical – Local and focal disease control	Impact of the extent of surgical resection on the prognosis of high-risk abdominal neuroblastoma	Yuki Yamamoto	Japan
PP-211		Group B	Clinical – Local and focal disease control	FNH lesions in patients after treatment for neuroblastoma - analysis of potential risk factors	Urszula Zebrowska	Poland
PP-212		Group B	Developmental Therapeutics – Immunology	The Immune Landscape in Neuroblastoma Bone Marrow Metastases	Gustav Christensson	Sweden
PP-213		Group B	Developmental Therapeutics – Immunology	A study of Dinutuximab $\boldsymbol{\beta}$ in the treatment of children with recurrent/refractory neuroblastoma	Hong Yan Liu	China
PP-214		Group B	Developmental Therapeutics – Immunology	Unleashing the power of neutrophils to tackle Neuroblastoma: combination of CD47 blockade and IgA activation in one bispecific molecule	Ida Christina Van Der Peet	Netherlands
PP-215		Group B	Developmental Therapeutics – Immunology	Antibody-dependent cellular cytotoxicity of induced pluripotent stem cell-derived natural killer T cells by anti-GD2 mAbs for neuroblastoma	Katsuhiro Nishimura	Japan
PP-216		Group B	Developmental Therapeutics – Immunology	Inhibition of myeloid-derived suppressor cells by SSRIs antidepressants: implications for neuroblastoma immunotherapy	Konstantinos Stamatiou	UK
PP-217		Group B	Developmental Therapeutics – Immunology	High-throughput compound screening to increase the efficacy of CAR-T cell therapy against neuroblastoma with combination treatments	Liselotte E. Baaij	Netherlands
PP-218		Group B	Developmental Therapeutics – Immunology	From Bench to Bedside: ABTL0812 and Immunotherapy as a Breakthrough Strategy for Neuroblastoma	María J Pérez García	Spain
PP-219		Group B	Developmental Therapeutics – Molecular Targeting	Functional loss of BAX in leuroblastoma: Insights from a clinical case and in vitro drug sensitivity assays	Adrià Molero Valenzuela	Spain
PP-220	Rapid Fire Session 2	Group B	Developmental Therapeutics – Molecular Targeting	Potential therapeutic targets for {ATRX}-aberrant neuroblastoma revealed by genome-wide CRISPR-Cas9 synthetic lethality screens	Fenja L. Fahrig	Netherlands
PP-221		Group B	Developmental Therapeutics – Molecular Targeting	Investigating Molecular Glues as a New Therapeutic Approach to High-Risk Neuroblastoma	Ian Delahunty	US
PP-222		Group B	Developmental Therapeutics – Molecular Targeting	Development of a novel agent for non-invasive immunotherapy target detection and radiopharmaceutical therapy	Ira Phadke	US
PP-223		Group B	Developmental Therapeutics – Molecular Targeting	Pre-clinical evaluation of next-generation RRM2 and CHK1 inhibitors for synergistic drug interactions in neuroblastoma	Iris Nelen	Belgium
PP-224		Group B	Developmental Therapeutics – Molecular Targeting	A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma	Isabel Soria Bretones	Canada
PP-225		Group B	Developmental Therapeutics – Molecular Targeting	Mitochondrial synthetic lethality reveals a novel strategy to target multidrug-resistant MYC- driven neuroblastoma	Jan Skoda	Czech Republic
PP-226		Group B	Developmental Therapeutics – Molecular Targeting	Combined Targeting of PRDX6 and GSTP1 as a Potential Differentiation Strategy for Treatment of Childhood Neuroblastoma	Judit Liaño Pons	Sweden
PP-227		Group B	Developmental Therapeutics – Molecular Targeting	CDK12 as an entry point for novel combination therapy in high-risk neuroblastoma	Kaat Durinck	Belgium
PP-228		Group B	Developmental Therapeutics – Molecular Targeting	Targeting MYCN via the epitranscriptomic modulator bisantrene	Liron D. Grossmann	Israel
PP-229		Group B	Developmental Therapeutics – Molecular Targeting	PHF6-driven RRM2 recruitment to stalled replication forks mitigates replicative stress in neuroblastoma: a potential therapeutic target	Lisa Depestel	Belgium
PP-230		Group B	Developmental Therapeutics – Molecular Targeting	Development of DNA damage response-targeting prodrugs as novel therapeutics for neuroblastoma	Louise Kate Stevenson	UK
PP-231		Group B	Developmental Therapeutics – Molecular Targeting	Interplay between metabolic reprogramming and the tumor microenvironment for development of precision medicine strategies for neuroblastoma	Lourdes Sainero Alcolado	Sweden
PP-232		Group B	Developmental Therapeutics – Molecular Targeting	MultiOmics approach reveals metabolic vulnerabilities in Serine Biosynthesis Pathway in MYCN-amplified Neuroblastoma cell lines	Marieke Van De Mheen	Netherlands
PP-233		Group B	Developmental Therapeutics – Molecular Targeting	Identifying EZH2 inhibitor combinations for (ATRX aberrant) neuroblastoma	Marlinde L. Van Den Boogaard	Netherlands
PP-234		Group B	Developmental Therapeutics – Molecular Targeting	Unveiling novel precision treatments for high-risk neuroblastoma harboring ARID1A/B molecular alterations	Marta Miera-Maluenda	Spain
PP-235		Group B	Developmental Therapeutics – Molecular Targeting	Inhibition of ROCK2 offers a novel approach to target metastatic spread in neuroblastoma	Nicola Bell	Sweden
PP-236		Group B	Developmental Therapeutics – Molecular Targeting	Combinatorial differentiation therapy for neuroblastoma: investigating the synergy of retinoic acid with CDK4/6 inhibition for clinical translation	Perla Pucci	UK
PP-237		Group B	Developmental Therapeutics – Molecular Targeting	GATA3-mediated upregulation of CDC20 facilitates tumor growth and metastasis through activation of Bcl-2/Bax pathway and EMT process in neuroblastoma	Yizhuo Zhang	China
PP-238	Rapid Fire Session 2	Group B	Developmental Therapeutics – Preclinical models of disease	Functional profiling on {ex vivo} neuroblastoma models: global collaboration to drive implementation in precision medicine	Eleonora Jacoba Looze	Netherlands



Poster	Rapid Fire	Poster	Торіс	Title	Presenter	Country
Number	Session	Group				
PP-239		Group B	Developmental Therapeutics – Preclinical models of disease	Preclinical models of ALK-inhibitor resistant neuroblastoma for the discovery of circular RNA biomarkers	Johannes Markus Riepl	Germany
PP-240		Group B	Developmental Therapeutics – Preclinical models of disease	The Zika Viral Therapy of High-Risk Neuroblastoma Confers a Dramatic Survival Advantage in Chemotherapy Resistant and Recurrent Tumors	Joseph Mazar	US
PP-241		Group B	Developmental Therapeutics – Preclinical models of disease	Characterizing Early Metastatic Dissemination in a MYCN-Driven Zebrafish Model of High- Risk Neuroblastoma	Kyle D Woodward	US
PP-242		Group B	Developmental Therapeutics – Preclinical models of disease	Development of immunocompetent transplantable transgenic mouse and rat models of neuroblastoma	Lasse Vleminckx	Belgium
PP-2/3		Group B		Atonyastatin a notential ototovicity protector, does not alter cytotovic response to	Manikantha Dunna	115
11-240		Огодр В	Preclinical models of disease	chemotherapy in neuroblastoma patient-derived models		00
PP-244		Group B	Developmental Therapeutics – Preclinical models of disease	Pomiferin induces anti-proliferative and pro- death effects in high-risk neuroblastoma cells by modulating multiple cell death pathways	Manu Gnanamony	US
PP-245		Group B	Developmental Therapeutics – Preclinical models of disease	Biomechanics in zebrafish and patient neuroblastoma	Mareike Wolff	Germany
PP-246	Rapid Fire Session 2	Group B	Developmental Therapeutics – Preclinical models of disease	Optimized Syngeneic Neuroblastoma Models to Advance Cell Therapies	Ying Wang	US
PP-247		Group C	Basic Science – Developmental biology	Molecular mechanisms of neurogenic tumor maturation	Alexander E. Druy	Russia
PP-248	Rapid Fire Session 3	Group C	Basic Science – Developmental biology	Evaluation of Indocyanine Green-Labeled Dinutuximab as a Novel In Vivo Molecular Imaging Agent for Neuroblastoma: an Orthotopic Murine Model	William G Lee	US
PP-249		Group C	Basic Science – Developmental biology	High-throughput drug screen of patients' biopsies to identify therapeutic strategies for treating pediatric patients: set-up protocol on PDX models	Angela Bellini	France
PP-250	Rapid Fire Session 3	Group C	Basic Science – Developmental biology	Investigating the functional significance NB risk locus 6p22.3: Role of ATXN1-AS1 and NB specific super enhancer in NB development and progression	Kamali Nagarajan	Sweden
PP-251		Group C	Basic Science – Developmental biology	Exploring the involvement of SOX10+/SOX2+ sustentacular cells in neuroblastoma development	Petra Bullová	Sweden
PP-252		Group C	Basic Science – Developmental biology	A novel small molecule drug ACT001 inhibits NB metastasis via modulating the STAT1/TEAD4/YAP1 axis	Qiang Zhao	China
PP-253		Group C	Basic Science – Developmental biology	UBE2C Regulates Neuroblastoma Differentiation through PINK1-Mediated Mitophagy	Qiang Zhao	China
PP-254		Group C	Basic Science – Developmental biology	The effect of different pre-stimulated umbilical cord mesenchymal stem cells conditioned medium on the sensitivity of NB cells to cisplatin	FuLi	China
PP-255		Group C	Basic Science – Developmental biology	KPNA2: a novel candidate G-quadruplex binding protein in neuroblastoma	Soetkin Leys	Belgium
PP-256		Group C	Basic Science – Developmental biology	Transcriptomic signature distinguishes spontaneous regression from tumor progression in neuroblastoma-prone Th-MYCN mice	Shoma Tsubota	Japan
PP-257		Group C	Basic Science – Developmental biology	Targeting β3-Adrenergic Receptor and Ephrin B4 Pathways as a Therapeutic Strategy in High- Risk Neuroblastoma	Rachele Amato	Italy
PP-258		Group C	Basic Science – Developmental biology	The effect of celastrol on proliferation of neuroblastoma cells	FuLi	China
PP-259		Group C	Basic Science – Immunology & Tumor Microenvironment	High dimensional profiling of immune landscape in Neuroblastoma	Alexia Gazeu	France
PP-260		Group C	Basic Science – Immunology & Tumor Microenvironment	High expression of CCL2 correlated with dendritic cell recruitment in low-risk neuroblastomas associated with opsoclonus-myoclonus syndrome	Alexia Gazeu	France
PP-261		Group C	Basic Science – Immunology & Tumor Microenvironment	MYCN-driven neuroblastoma consumes exogenous cyst(e)ine to promote immune- suppression and tumor progression	Amber B Wolf	US
PP-262		Group C	Basic Science – Immunology & Tumor Microenvironment	Spectral flow cytometry reveals immune regulation of detailed lymphocyte and myeloid populations in neuroblastoma	Anne L Borst	Netherlands
PP-263		Group C	Basic Science – Immunology & Tumor Microenvironment	Spatiotemporal mapping of the neuroblastoma tumor microenvironment in response to drug- enhanced replicative stress	Annelies Van Hemelryk	Belgium
PP-264		Group C	Basic Science – Immunology & Tumor Microenvironment	Recapitulating the context of Neuroblastoma emergence in the avian embryo reveals interactions between early waves of macrophages and malignant cells	Audrey Prunet	France
PP-265		Group C	Basic Science – Immunology & Tumor Microenvironment	High fat diet accelerates NB tumor progression by creating an immune suppressive tumor microenvironment	Lingzhi Li	US
PP-266		Group C	Basic Science – Immunology & Tumor Microenvironment	Chimeric Antigen Strategies to Bridge Species Barriers in Preclinical Testing of Chimeric Antigen Receptor T Cell Therapy for Neuroblastoma	Efrosiniia Talalai	Germany
PP-267		Group C	Basic Science – Immunology & Tumor Microenvironment	Expanded T cell clones in neuroblastoma persist throughout chemotherapy and display a druggable dysfunctional profile	Elisa Zappa	Netherlands
PP-268		Group C	Basic Science – Immunology & Tumor Microenvironment	De novo GDP-Fucose Synthesis is a Novel Regulator of MYCN-amplified Neuroblastoma Myeloid Cell Trafficking and Tumor Progression	Eric J. Rellinger	US
PP-269		Group C	Basic Science – Immunology & Tumor Microenvironment	Spatiotemporal characterization of mouse MYCN-driven neuroblastoma using 17-plex immunofluorescence	Eva Galateau	France
PP-270		Group C	Basic Science – Immunology & Tumor Microenvironment	Neuropeptide Y receptor 5 in adrenergic and mesenchymal neuroblastoma cells	Ewa Krawczyk	US
PP-271		Group C	Basic Science – Immunology & Tumor Microenvironment	Modeling neuroblastoma bone marrow metastasis {in vitro}	Sonia Hernandez	US
PP-272		Group C	Basic Science – Immunology & Tumor Microenvironment	Spatial organization and function of RNA in primary neuroblastomas and their TME	Florian Bartsch	Germany



Poster Number	Rapid Fire Session	Poster Group	Торіс	Title	Presenter	Country
PP-273		Group C	Basic Science – Immunology & Tumor Microenvironment	Mannose promotes myo-inositol-mediated angiogenesis in the neuroblastoma microenvironment	Ling Tao	China
PP-274	Rapid Fire Session 3	Group C	Basic Science – Molecular analyses (proteo epigenomics)	A new core regulatory circuitry driving a noradrenergic to mesenchymal transition highlights YAP/TAZ as critical players of neuroblastoma plasticity	Cécile Thirant	France
PP-275		Group C	Basic Science – Molecular analyses (proteo epigenomics)	miR footprint from infants with neuroblastoma predicts disease prognosis	Natarajan Aravindan	US
PP-276		Group C	Basic Science – Molecular analyses (proteo epigenomics)	Whole Exome Sequencing Replaces Conventional Molecular Techniques for Prognostic Markers Detection in Neuroblastoma	Rixt S. Bruinsma	Netherlands
PP-277	Rapid Fire Session 3	Group C	Basic Science – Molecular analyses (proteo epigenomics)	Unmasking Oncogenic Drivers in Neuroblastoma Through Integrative Analysis and Functional Validation	Ryan Borchert	US
PP-278		Group C	Basic Science – Molecular analyses (proteo epigenomics)	TPX2 is a downstream target of the eIF4A controlled translation program in neuroblastoma	Sarah Lee Bekaert	Belgium
PP-279		Group C	Basic Science – Molecular analyses (proteo epigenomics)	KIF26A is a novel super-enhancer-driven gene activated by master TFs and potentiates ribosome biogenesis in neuroblastoma	Shibei Du	China
PP-280		Group C	Basic Science – Molecular analyses (proteo epigenomics)	Deciphering the mechanisms of Neuroblastoma metastasis by multi-omics analysis	Silvia Mateo Lozano	Spain
PP-281		Group C	Basic Science – Molecular analyses (proteo epigenomics)	Long-read sequencing identifies full-length circular RNAs linked with therapy resistance in pediatric cancers	Steffen Eberhard Fuchs	Germany
PP-282		Group C	Basic Science – Molecular analyses (proteo epigenomics)	Investigating mechanisms responsible for MAP kinase pathway resistance in RAS-altered Neuroblastoma cells	Subhra Dash	US
PP-283		Group C	Basic Science – Molecular analyses (proteo epigenomics)	Exploring the regulation of RNA sorting by MYCN in neuroblastoma	Theresa Schönrock	Germany
PP-284		Group C	Basic Science – Molecular analyses (proteo epigenomics)	Elucidating the Role of TET Enzymes in PRC2-Mediated Gene Regulation and Resistance to Tazemetostat	Varsha Gupta	US
PP-285		Group C	Basic Science – Molecular analyses (proteo epigenomics)	KAT2A and MYCN interact to drive oncogenic transcriptional regulation in neuroblastoma	Wendy Z. Fang	US
PP-286		Group C	Basic Science – Molecular analyses (proteo epigenomics)	Analysis of gene phenotype characteristics of high-risk recurrent neuroblastoma without N- MYC amplification	Yi Zhang	China
PP-287		Group C	Basic Science – Molecular analyses (proteo epigenomics)	GJC1, the Marker of Immature phenotype, Promotes the Progression of Neuroblastoma	Yong Zhan	China
PP-288		Group C	Basic Science – Molecular analyses (proteo epigenomics)	The Role of NDUFS6 in Neuroblastoma Progression and Exploration of Targeted Intervention Strategies	Yong Zhan	China
PP-289		Group C	Basic Science – Molecular analyses (proteo epigenomics)	BRCA2 as a Treatment Stratification Marker for DNA-damaging Cytotoxics during Induction Chemotherapy in Neuroblastoma	Zhi Xiong Chen	Singapore
PP-290		Group C	Basic Science – Molecular analyses (proteo epigenomics)	RNA m6A Modification Regulates the MES-ADRN Transition in Neuroblastoma	Zhixiang Wu	China
PP-291		Group C	Clinical – Biomarkers & Imaging	Impact of Post-Consolidation Curie Scores on Outcomes in High-Risk Neuroblastoma Patients Undergoing Autologous Stem Cell Transplantation	Erin T Hamanishi	US
PP-292		Group C	Clinical – Biomarkers & Imaging	Prognostic Indications for Circulating Tumor DNA Monitoring in High Risk Neuroblastoma: Single Institutional Experience and Insights	Chelsee Greer	US
PP-293		Group C	Clinical – Biomarkers & Imaging	Oncogene amplification and p53 pathway alterations identify subsets of intermediate-risk neuroblastoma patients with inferior outcome: A SIOPEN study	Hannah E Hartley	Australia
PP-294		Group C	Clinical – Biomarkers & Imaging	A Potential Sanctuary Site of Relapse in a Teenage Female Neuroblastoma Patient: A Case Report	Brittany Frazer	US
PP-295		Group C	Clinical – Clinical research	Influence of skeletal muscle and visceral adipose on long-term survival in high-risk neuroblastoma patients	Dapeng Jiang	China
PP-296		Group C	Clinical – Clinical research	End-of-Induction Response as a Surrogate Endpoint for Overall Survival in High-Risk Neuroblastoma	Arthur Berg	US
PP-297		Group C	Clinical – Clinical research	Imaging Assessment of the Risk of the Adamkiewicz Artery Injury in Lower Mediastinal Neuroblastoma	Akihiro Yoneda	Japan
PP-298		Group C	Clinical – Clinical research	Genetic analyses of neuroblastomas in UK patients older than 10 years	Azhar Hafeez	UK
PP-299		Group C	Clinical – Clinical research	Patterns of relapse and outcomes for children with Relapsed/Refractory High-Risk Neuroblastoma in Australian and New Zealand	Bhavna Padhye	Australia
PP-300		Group C	Clinical – Clinical research	Diagnostics and treatment of neuroblastoma in adults: single center experience in 25 patients	Amina Suleymanova	Russia
PP-301		Group C	Clinical – Clinical research	Chemoimmunotherapy with Irinotecan, Temozolomide and Dinutuximab beta for children with refractory/relapsed neuroblastoma: single center experience	Amina Suleymanova	Russia
PP-302		Group C	Clinical – Clinical research	Anti-GD2 based therapy as the possible treatment of consecutive relapses of neuroblastoma – case report with review of literature	Aleksandra Wieczorek	Poland
PP-303		Group C	Clinical – Clinical research	ALK inhibitors in treatment of patients with high-risk neuroblastoma – efficacy and safety in real-life data analysis	Aleksandra Wieczorek	Poland
PP-304		Group C	Clinical – Clinical research	Chemo-immunotherapy rescue for high-risk neuroblastoma patients progressing before high- dose chemotherapy: real-world data from the SACHA-France study	Claudia Pasqualini	France
PP-305		Group C	Clinical – Clinical research	Overcoming resistance to ALK inhibitors through BCL-2 inhibition: a report on combination therapy in two patients	Bram De Wilde	Belgium
PP-306		Group C	Clinical – Clinical research	Predictors of Response to 1311- Metaiodobenzylguanidine in the Anti-GD2 Immunotherapy Era	Benjamin J. Lerman	US



Poster	Rapid Fire	Poster	Торіс	Title	Presenter	Country
Number	Session	Group				
PP-307		Group C	Clinical – Clinical research	Rapid COJEC without myeloablative therapy (MAT) for high-risk neuroblastoma (HR-NB)	Brian H Kushner	US
PP-308		Group C	Clinical – Clinical research	Naxitamab Plus Novel Scheduling of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) For Primary Refractory High-Risk Neuroblastoma (HR-NB)	Brian H Kushner	US
PP-309		Group C	Clinical – Clinical research	Novel Shortened Induction Chemotherapy For High-Risk Neuroblastoma: Tolerability, Response, and Outcome Without Myeloablative Therapy	Brian H Kushner	US
PP-310		Group C	Clinical – Clinical research	Treatment strategies for high-risk stage IV neuroblastoma with isolated CNS relapse after allogenic KIR-ligand mismatched cord blood transplantation	Daiki Yamashita	Japan
PP-311	Rapid Fire Session 3	Group C	Clinical – Clinical research	Long-term outcomes of patients with relapsed/refractory neuroblastoma treated on ANBL1221: A report from the Children's Oncology Group	Elizabeth Sokol	US
PP-312		Group C	Clinical – Clinical research	Survival following relapse of high-risk neuroblastoma has improved over time: A study from the International Neuroblastoma Risk Group (INRG) database	Daniel A Morgenstern	Canada
PP-313		Group C	Clinical – Clinical research	Clinical and biological factors associated with length of survival following relapse in UK patients with high risk neuroblastoma	Deborah A. Tweddle	UK
PP-314		Group C	Clinical – Clinical research	Germline 16p11.2 microdeletion and neuroblastoma: two cases with different variants and additional constitutional conv number abnormalities	Deborah A. Tweddle	Malaysia
PP-315		Group C	Clinical – Clinical research	Tolerability and toxicity of induction chemoimmunotherapy with dinutuximab beta in newly	Denis Kachanov	Russia
PP-316		Group C	Clinical – Clinical research	Improved End-of-Induction Response for High-Risk Neuroblastoma treated with Champiomunotherany, Modified N7 regimen with Disutivingh beta	Evelyn Lu	Hong Kong
PP-317		Group C	Clinical – Clinical research	Canadian Landscape of Therapy for Children with High-Risk Neuroblastoma	Gabrielle Herzenberg	Canada
PP-318		Group C	Clinical – Clinical research	Safety Comparison of Two Different Dosing Regimens for Oral Eflornithine (DFMO) In	Genevieve Bergendahl	US
PP-319		Group C	Clinical – Clinical research	Systems level immune monitoring studying the effects of chemotherapy on the immune	Gustav Hedberg	Sweden
PP-320		Group C	Clinical – Clinical research	Analysis of the therapeutic effect of immunoglobulin shock therapy in patients with	Hong Yan Liu	China
PP-321	Rapid Fire	Group C	Clinical – Clinical research	Enhanced Recovery after Surgery (ERAS) improves length of stay and complications after recording of addapting lowerbloctoms	Sara A Mansfield	US
PP-322	Rapid Fire	Group C	Clinical – Clinical research	FDG and FDOPA PET scans at diagnosis predict tumor behavior and gross total resection in	Yen Lin Liu	Taiwan
PP-323	Sessions	Group C	Clinical – Clinical research	A Rare Case of Pediatric High-Risk Neuroblastoma in the Setting of Achondroplasia	Alyssa M Greenwell	US
PP-324		Group C	Clinical – Social determinant of health	Bridging the Gap: Establishing Consensus for Improving Neuroblastoma Diagnosis and Care Experiences for Patients and Caregivers	Vickie Buenger	US
PP-325		Group C	Developmental Therapeutics – Immunology	Efficacy of Murine Chimeric TGFβ Signaling Receptor m(CTSR)-B7H3 CAR-T Cells in a Syngeneic Murine Neuroblastoma Model	Michael Migotsky	US
PP-326		Group C	Developmental Therapeutics – Immunology	HSAN is an anti-neuroblastoma monoclonal antibody that binds to GFRA2	Michelle Keyel	US
PP-327		Group C	Developmental Therapeutics – Immunology	PD-1 blockade enhances topotecan/temozolomide and anti-GD2 chemoimmunotherapy in high-risk neuroblastoma	Peter M. Ahrenberg	Germany
PP-328		Group C	Developmental Therapeutics – Immunology	On again, off again: protein degrader approaches finetune the therapeutic window of CAR T cell therapies	Ronja Van Berkum	Netherlands
PP-329		Group C	Developmental Therapeutics – Immunology	Anti-Neuroblastoma efficacy of high-affinity anti-GD2 antibodies is impaired by the target- mediated drug disposition (TMDD) effect	Sascha Troschke Meurer	Germany
PP-330		Group C	Developmental Therapeutics – Immunology	CD44 and PHOX2B as markers of adrenergic-mesenchymal transition in NB and predictors of suscentibility to chemoimmunotherapy and E7H2 Inhibition	Sascha Troschke Meurer	Germany
PP-331		Group C	Developmental Therapeutics –	Irinotecan Modulates Immune Checkpoints in Neuroblastoma: Implications for Chemo- Immunotherany	Tom Lapidus	Israel
PP-332		Group C	Developmental Therapeutics –	Long-Term Follow-Up of GD2 monoclonal antibody in the treatment of Chinese children with Hinth-Bick and Balansed/Befracton/Neuroblastoma	Xiaojun Yuan	China
PP-333		Group C	Developmental Therapeutics –	Umbilical cord blood natural killer cells improve anti-GD2 efficacy in neuroblastoma	Yizhuo Zhang	China
PP-334		Group C	Developmental Therapeutics –	Preclinical evaluation of GSPT1 degradation in high-risk neuroblastoma	Aleksandra Adamska	Sweden
PP-335		Group C	Developmental Therapeutics –	Enhancing the therapeutic coverage of peptide-centric CAR T cell therapy in high-risk	Alvin Farrel	US
PP-336		Group C	Developmental Therapeutics –	Pre-emptive targeted therapy to optimise high-risk neuroblastoma treatment	Alvin Kamili	Australia
PP-337		Group C	Developmental Therapeutics –	Identifying synergistic combinations with the BCL2 inhibitor venetoclax for high-risk	Alvin Kamili	Australia
PP-338		Group C	Molecular Targeting	High-throughput screening identifies histone chaperone FACT inhibitor CBL0137 and PARP	Amanda Wanninayaka	Australia
PP-339	Rapid Fire	Group C	Developmental Therapeutics –	Characterization of the functional impact of G4 ligands on telomere maintenance	Anna Borovkov	France
PP-340	36331011 3	Group C	Developmental Therapeutics – Molecular Targeting	Elucidating TWIST1 interactome and downstream target genes in high-risk neuroblastoma for novel therapeutic target discovery	Annick Mühlethaler Mottet	Switzerland



Poster	Rapid Fire	Poster	Торіс	Title	Presenter	Country
Number	Session	Group				
PP-341		Group C	Developmental Therapeutics –	Anaplastic Lymphoma Kinase interacts and activates members of the solute carrier family	Bengt Hallberg	Sweden
			Molecular Targeting	transport proteins to promote cell growth		
PP-342		Group C	Developmental Therapeutics –	Targeting Distinct Neuroblastoma Cell States: NCAM1+ Adrenergic Tumor Cells and FGFR1+	Celine Hafkesbrink	Sweden
			Molecular Targeting	Resistant Mesenchymal Cells		
PP-343		Group C	Developmental Therapeutics –	Synthesis and effects of Melphalan-Benzylguanidine-hybrids on neuroblastoma and non-	Christina Parpoulas	Germany
			Molecular Targeting	neuroblastoma cells		
PP-344		Group C	Developmental Therapeutics –	Vertical Targeting of AKT and MEK Signaling as well as Dual Targeting of AKT and MEK	Dongqing Xu	China
			Molecular Targeting	Signaling Is Synergistic in Neuroblastoma		
PP-345		Group C	Developmental Therapeutics –	CID-078, an orally bioavailable cyclin A/B-RxL inhibitor elicits anti-tumor activity in	Dylan M.M. Jongerius	Netherlands
			Molecular Targeting	neuroblastoma models	· •	
PP-346		Group C	Developmental Therapeutics –	EZH2 inhibition re-sensitizes AHR expression and enhances its ligand-activated signaling in	Farhan Azhwin Maulana	Taiwan
			Molecular Targeting	therapeutic vulnerabilities of neuroblastoma cells		
PP-347		Group C	Developmental Therapeutics –	EZH2 inhibition de-represses AHR expression and enhances its ligand-activated signaling in	Farhan Azhwin Maulana	Taiwan
			Molecular Targeting	neuroblastoma therapy		
PP-348		Group C	Developmental Therapeutics –	Differences in chromatin response to retinoic acid are seen in neuroblastoma with {ATRX} in-	Federica Lorenzi	UK
			Molecular Targeting	frame deletions versus {ATRX} loss-of-function		
PP-349		Group C	Developmental Therapeutics –	Nanoarchitectonics of the M13 phage provides a potent and specific anti- GD2 vector	Giorgio Milazzo	Italy
			Molecular Targeting	platform for Neuroblastoma Therapy	-	-
PP-350		Group C	Developmental Therapeutics –	HDAC 1/2 inhibition suppresses telomerase activity in TERT-rearranged neuroblastoma	Hedwig Elisabeth	Germany
			Molecular Targeting		Deubzer	
PP-351		Group C	Developmental Therapeutics –	Deciphering the code of MYCN protein in neuroblastoma: unveiling its secrets through	Xingyu Liu	US
			Molecular Targeting	barcoded mutagenesis screen and single-cell RNA sequencing analys		
PP-352		Group C	Developmental Therapeutics –	HMOX1 mediates the ferroptosis that is induced by a small molecule compound DMAMCL in	Zhijie Li	China
			Molecular Targeting	a MYCN-dependent manner in Neuroblastoma cells		
PP-353		Group C	Developmental Therapeutics –	A 3D bioprinted immunocompetent and perfusable model of neuroblastoma to study the	Jenny Shim	US
			Preclinical models of disease	tumor microenvironment impact on therapy response		
PP-354		Group C	Developmental Therapeutics –	Realizing the potential of DFMO + AMXT1501 polyamine depletion therapy by mitigating	Michelle Haber	Australia
			Preclinical models of disease	cardiac and other toxicities		
PP-355	Rapid Fire	Group C	Developmental Therapeutics –	Characterizing a panel of neuroblastoma patient-derived xenografts for response to induction	Min Hee Kang	US
	Session 3		Preclinical models of disease	and salvage chemotherapy		
PP-356	Rapid Fire	Group C	Developmental Therapeutics –	BMP signaling determines neuroblastoma cell fate and sensitivity to retinoic acid	Min Pan	US
	Session 3		Preclinical models of disease			
PP-357		Group C	Developmental Therapeutics –	Modelling neuroblastoma using induced pluripotent stem cells derived from patients with	Mingzhi Liu	Sweden
			Preclinical models of disease	{ALKR1275Q}germline mutation		
PP-358		Group C	Developmental Therapeutics –	Humanized MISTRG mice to model neuroblastoma immunotherapy research	Nikolina Bąbała	Netherlands
			Preclinical models of disease			
PP-359		Group C	Developmental Therapeutics –	Identifying mechanisms for development of high-risk neuroblastoma	Panagiotis Alkinoos	Sweden
			Preclinical models of disease		Polychronopoulos	
PP-360		Group C	Developmental Therapeutics –	An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical	Paul Geeleher	US
			Preclinical models of disease	models uncovers divergent mesenchymal-like gene expression program		
PP-361		Group C	Developmental Therapeutics –	A Spatial Transcriptomic Exploration of the High-Risk Neuroblastoma Tumor	Peter Merseburger	Belgium
			Preclinical models of disease	Microenvironment in Response to Inhibition of the DNA Damage Response		
PP-362		Group C	Developmental Therapeutics –	A Ketogenic Diet boosts Neuroblastoma Chemo- and Immunotherapy in mice	Victoria Stefan	Austria
			Preclinical models of disease			
PP-363		Group C	Developmental Therapeutics –	{In vivo} assessments of patient-specific {CHEK2} genetic variants associated with high-risk	Xueting Xiong	Canada
			Preclinical models of disease	neuroblastoma	-	
·		•				